Editorial

Cancer Drug Resistance

Open Access

Check for updates

Acknowledgement to reviewers of *Cancer Drug Resistance* in 2018

Cancer Drug Resistance Editorial Office

OAE Publishing Inc., Chaoyang District, Beijing 100027, China.

Correspondence to: OAE Publishing Inc., Suite 601, Tower A, TYG Center, C2 North Road, East 3rd Ring Road, Chaoyang District, Beijing 100027, China. E-mail: editorial@cdrjournal.com

How to cite this article: Cancer Drug Resistance Editorial Office. Acknowledgement to reviewers of *Cancer Drug Resistance* in 2018. *Cancer Drug Resist* 2018;1:198-9. http://dx.doi.org/10.20517/cdr.2018.29

Received: 3 Dec 2018 Accepted: 7 Dec 2018 Published: 19 Dec 2018

Science Editors: Godefridus J. Peters, Aamir Ahmad Copy Editor: Cai-Hong Wang Production Editor: Huan-Liang Wu

The editors of the *Cancer Drug Resistance* would like to take this opportunity to express their sincere gratitude to the reviewers and guest editors for assessing manuscripts in 2018 [Table 1].

Names	
Amstutz, Ursula	Jansen, Gerrit
Ahmad, Aamir	Jiang, Zhao
Balboni, Beatrice	Joerger, Markus
Ciriza, Jesús	Kwok, Hang Fai
Cloos, Jacqueline	Link, Wolfgang
Del Re, Marzia	Marchesi, Federica
El Hassouni, Btissame	Matsuura, Yoshiyuki
Fenton, Tim	Michaelis, Martin
Fiandalo, Michael	Mini, Enrico
Firuzi, Omid	Nobili, Stefania
Gan, Boyi	Nowak-Sliwinska, Patrycja
Garajová, Ingrid	Pasternak, Amy
Garrett, Michelle	Perego, Paola
Giovannetti, Elisa	Phillips, Roger M
Gong, Li	Pore, Milind
Griffiths, Elizabeth	Rodriguez, Jose Antonio
Huang, Shiliang	Rosière, Rémi
Huisman, M.C.	Wass, Mark
Hussain, Suleman	Zaffaroni, Nadia

Table 1. Names of reviewers and guest editors

The listed reviewers have our sincere gratitude. They can also get their *Reviewer Recognition Certificates* by building their peer review profiles on Publons (https://publons.com).

© The Author(s) 2018. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.





DECLARATIONS

Authors' contributions

Writing and revision of the article and approved the final version: Cancer Drug Resistance Editorial Office

Availability of data and materials

Not applicable.

Financial support and sponsorship None.

Conflicts of interest

All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate Not applicable.

Consent for publication Not applicable.

Copyright © The Author(s) 2018.